Zura Bio(ZURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZURA Zura Bio

Pre-Mkt 12-19 05:31:12 EST

4.27

-0.01

-0.23%

High4.45	Low4.27	Vol250.48K
Open4.34	D1 Closing4.28	Amplitude4.21%
Mkt Cap277.65M	Tradable Cap105.36M	Total Shares65.02M
T/O1.09M	T/O Rate1.02%	Tradable Shares24.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZURA","market":"US","secType":"STK","nameCN":"Zura Bio","latestPrice":4.27,"timestamp":1766091600000,"preClose":4.28,"halted":0,"volume":250476,"delay":0,"floatShares":24675000,"shares":65023300,"eps":-0.670864,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"12-19 05:31:12 EST","open":4.34,"high":4.45,"low":4.27,"amount":1088661.1967868,"amplitude":0.042056,"askPrice":4.42,"askSize":500,"bidPrice":3.75,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.670864,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":4.27,"postHourTrading":{"tag":"盘后","latestPrice":4.27,"preClose":4.27,"latestTime":"18:39 EST","volume":1152,"amount":4917.92,"timestamp":1766101142426},"volumeRatio":0.46467466333115437,"impliedVol":2.7496,"impliedVolPercentile":0.8956},"requestUrl":"/m/hq/s/ZURA/tweets","defaultTab":"tweets","newsList":[{"id":"2592990159","title":"Zura Bio Director Arnout Ploos van Amstel Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2592990159","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592990159?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:02","pubTimestamp":1765976530,"startTime":"0","endTime":"0","summary":"Arnout Ploos van Amstel has resigned from the Board of Directors and the Nominating and Governance Committee of Zura Bio Ltd., effective immediately. The company stated that his resignation was not due to any disagreement regarding company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL992zKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2591094625","title":"December 2025's Top Penny Stocks With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2591094625","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591094625?lang=en_us&edition=fundamental","pubTime":"2025-12-16 01:05","pubTimestamp":1765818313,"startTime":"0","endTime":"0","summary":"As the United States market experiences fluctuations, with technology shares weighing on major indices like the Nasdaq, investors are closely monitoring economic indicators and Federal Reserve actions. In this context, penny stocks—often seen as smaller or newer companies—remain a compelling area of interest due to their potential for growth when backed by strong financials. Despite being an outdated term, these stocks can offer unique opportunities for investors seeking to uncover hidden...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orgo/organogenesis-holdings/news/december-2025s-top-penny-stocks-with-promising-potential","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-orgo/organogenesis-holdings/news/december-2025s-top-penny-stocks-with-promising-potential","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4134","DDL","LU0049112450.USD","PERF","LX","BK4204","LU1235295612.USD","WDH","BK4139","ORGO","BABB","LU1046422090.SGD","LCUT","MAPS","BK4551","NAMI","BK4505","BK4509","BK4113","BK4180","BK4023","BK4166","BK4531","BK4209","BK4526","BK4173","TUYA","ZURA","CINT","BK4539","BK4579"],"gpt_icon":0},{"id":"2583817516","title":"Zura Bio Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2583817516","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583817516?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:04","pubTimestamp":1763154240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 16:04 ET (21:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0},{"id":"2583561623","title":"Zura Bio Q4 EPS $(0.21) Misses $(0.18) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561623","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561623?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:32","pubTimestamp":1763033561,"startTime":"0","endTime":"0","summary":"Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 15.38 percent. This is a 19.23 percent increase over losses of $(0.26) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48829190/zura-bio-q4-eps-0-21-misses-0-18-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0},{"id":"2583561656","title":"Zura Bio reports third quarter net loss of $20.0 million on $139.0 million cash balance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561656","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561656?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033432,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd. reported a net loss of $20.0 million, or $0.21 per share, for the third quarter of 2025, compared to a net loss of $22.9 million, or $0.26 per share, for the same period in 2024. Research and development expenses were $11.9 million, up from $6.0 million in the third quarter of 2024, primarily due to the ongoing Phase 2 clinical trials of tibulizumab. General and administrative expenses were $7.6 million, down from $13.3 million in the prior year, mainly due to a one-time non-cash share-based compensation expense in 2024. As of September 30, 2025, Zura Bio held $139.0 million in cash and cash equivalents, expected to fund operations through 2027. The company continues to advance its Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis, with topline data from these studies expected in the second half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLbLCrWN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2583561513","title":"Zura Bio Q3 Income From Operations USD -19.519 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561513?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX3D020C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2583561188","title":"Zura Bio Ltd: Expects Existing Cash and Cash Equivalents to Be Sufficient to Support Planned Operations Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561188?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX3D020C:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2583616755","title":"Press Release: Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583616755","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583616755?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:30","pubTimestamp":1763033400,"startTime":"0","endTime":"0","summary":"--  Continued advancement of two Phase 2 clinical trials evaluating. sclerosis  , with topline data expected in the second half. --  Reported $139.0 million in cash and cash equivalents as of September. 30, 2025, which is expected to fund planned operations through 2027.Zura Bio Limited  , a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates.\"Both tibulizumab studies advanced during the quarter,\" said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Zura Bio. \"We continue to focus on disciplined study execution and patient enrollment across these important disease areas, with the aim of generating meaningful data.\". --  TibuSURE : The Phase 2 clinical trial in adults with SSc continued. to advance during the quarter. Topline data are expected in the fou","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2583561892","title":"Zura Bio Initiated at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561892","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561892?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:22","pubTimestamp":1763032920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 06:22 ET (11:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2580110214","title":"Zura Bio Ltd  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580110214","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580110214?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:49","pubTimestamp":1762181383,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd  expected to post a loss of18cents a share - Earnings Preview Zura Bio Ltd ZURA.OQ ZURA.O is expected to  show no change in quarterly revenue when it reports  results on November 5 (estim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2574179430","title":"Zura Bio CEO Takes Medical Leave, Interim Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2574179430","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574179430?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:43","pubTimestamp":1760100205,"startTime":"0","endTime":"0","summary":"Zura Bio ( ($ZURA) ) has issued an announcement. On October 8, 2025, Zura Bio Limited announced that its CEO, Robert Lisicki, will take a medical l...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zura-bio-ceo-takes-medical-leave-interim-appointed?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zura-bio-ceo-takes-medical-leave-interim-appointed?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2574176383","title":"BRIEF-Zura Bio Ltd - CEO Robert Lisicki To Take Medical Leave - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2574176383","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574176383?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:23","pubTimestamp":1760099028,"startTime":"0","endTime":"0","summary":"BRIEF-Zura Bio Ltd - CEO Robert Lisicki To Take Medical Leave - SEC FilingZura Bio Ltd ZURA.O:ZURA BIO LTD - CEO ROBERT LISICKI TO TAKE MEDICAL LEAVE - SEC FILINGZURA BIO LTD - KIM DAVIS APPOINTED INTERIM CEO OF CO - SEC FILINGSource text: [ID:n0001104659-25-098546]Further company coverage: ZURA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR0Z4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2574176844","title":"Zura Bio Ltd - Kim Davis Appointed Interim CEO of Co - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2574176844","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574176844?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:22","pubTimestamp":1760098921,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nFWN3VR0Z4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2574768961","title":"Zura Bio names Kim Davis interim CEO as Robert Lisicki takes medical leave","url":"https://stock-news.laohu8.com/highlight/detail?id=2574768961","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574768961?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:21","pubTimestamp":1760098870,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd. announced that Chief Executive Officer Robert Lisicki will take a medical leave of absence effective October 10, 2025. The Board of Directors has appointed Kim Davis, the current Chief Operating Officer, Chief Legal Officer, and Corporate Secretary, as interim Chief Executive Officer during this period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL7YCg9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2572371566","title":"Zura Bio Ltd. Adopts New Executive Severance Plan, Expanding Compensation and Benefits for Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2572371566","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572371566?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:11","pubTimestamp":1759263072,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd. has announced the adoption of a new Executive Severance Benefit Plan, extending enhanced severance benefits to certain employees, including the company's current named executive officers. Under the plan, the Chief Executive Officer is eligible for a lump sum payment equal to 12 months of base salary if terminated without cause or resigning for good reason, while other named executive officers are eligible for nine months of base salary. In the event of a termination within 12 months following a change in control, the CEO would receive 18 months of base salary and 150% of their target annual bonus, along with a prorated annual bonus and up to 18 months of COBRA premium reimbursement. Other named executive officers would be entitled to 12 months of base salary, 100% of their target annual bonus, a prorated annual bonus, and up to 12 months of COBRA reimbursement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDLbNx2F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA","BK4139"],"gpt_icon":0},{"id":"2571344854","title":"Zura Bio Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2571344854","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571344854?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:29","pubTimestamp":1759231740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2025 07:29 ET (11:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0},{"id":"2560917404","title":"Zura Bio Ltd. to Participate in Cantor Fitzgerald Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2560917404","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560917404?lang=en_us&edition=fundamental","pubTime":"2025-08-20 18:30","pubTimestamp":1755685813,"startTime":"0","endTime":"0","summary":"Zura Bio Ltd., a clinical-stage immunology company, is set to participate in the Cantor Fitzgerald Global Healthcare Conference in New York on September 4, 2025. The company's senior leadership team will present a fireside chat and conduct one-on-one investor meetings. A live webcast of the presentation will be accessible on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zura Bio Ltd. published the original content used to generate this news brief via Business Wire  on August 20, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250820:nNDL2WyVBn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2560193614","title":"Zura Bio Is Maintained at Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2560193614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560193614?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:05","pubTimestamp":1755601500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 07:05 ET (11:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0},{"id":"2560216704","title":"Zura Bio Limited : H.c. Wainwright Cuts Target Price to $2 From $3","url":"https://stock-news.laohu8.com/highlight/detail?id=2560216704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560216704?lang=en_us&edition=fundamental","pubTime":"2025-08-19 18:13","pubTimestamp":1755598436,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nAZN4DVCK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZURA"],"gpt_icon":0},{"id":"2559911426","title":"Zura Bio Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2559911426","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559911426?lang=en_us&edition=fundamental","pubTime":"2025-08-15 20:19","pubTimestamp":1755260340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 15, 2025 08:19 ET (12:19 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZURA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zurabio.com","stockEarnings":[{"period":"1week","weight":0.0569},{"period":"1month","weight":0.1149},{"period":"3month","weight":1.1457},{"period":"6month","weight":2.7788},{"period":"1year","weight":0.9234},{"period":"ytd","weight":0.708}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.158249},{"month":2,"riseRate":0.75,"avgChangeRate":0.007816},{"month":3,"riseRate":0.5,"avgChangeRate":0.020185},{"month":4,"riseRate":0.75,"avgChangeRate":0.079189},{"month":5,"riseRate":0.25,"avgChangeRate":-0.072869},{"month":6,"riseRate":0.75,"avgChangeRate":0.041052},{"month":7,"riseRate":0.75,"avgChangeRate":0.075734},{"month":8,"riseRate":0.75,"avgChangeRate":0.126932},{"month":9,"riseRate":0.5,"avgChangeRate":0.266974},{"month":10,"riseRate":0.6,"avgChangeRate":-0.062262},{"month":11,"riseRate":0.6,"avgChangeRate":-0.053189},{"month":12,"riseRate":0.4,"avgChangeRate":-0.02071}],"exchange":"NASDAQ","name":"Zura Bio","nameEN":"Zura Bio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zura Bio(ZURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zura Bio(ZURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zura Bio,ZURA,Zura Bio股票,Zura Bio股票老虎,Zura Bio股票老虎国际,Zura Bio行情,Zura Bio股票行情,Zura Bio股价,Zura Bio股市,Zura Bio股票价格,Zura Bio股票交易,Zura Bio股票购买,Zura Bio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zura Bio(ZURA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zura Bio(ZURA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction